Actively Recruiting
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
Led by Zhujiang Hospital · Updated on 2025-09-23
30
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with icaritin
CONDITIONS
Official Title
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects voluntarily agree and sign informed consent
- Male or female aged 18 to 75 years old
- Histopathologic diagnosis of hepatocellular carcinoma
- R0 resection performed within 4 to 8 weeks before recruitment
- Meet at least one high-risk factor for recurrence: BCLC stage B with more than 3 tumors including at least one larger than 3 cm, or a single tumor 5 cm or larger, or vascular invasion, or low differentiation grade, or capsular invasion or unclear border, or direct invasion of adjacent organs
- ECOG performance status score of 0-1 and Child-Pugh score of 5-6
- No prior anti-tumor therapy except 1-2 prophylactic TACE or HAIC treatments 4 to 8 weeks after surgery
- Prophylactic TACE or HAIC treatments allowed 4 to 8 weeks after surgery if needed
You will not qualify if you...
- Known sarcomatoid hepatocellular carcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or fibrolamellar hepatocellular carcinoma
- History of other malignancies within past 5 years or currently
- Severe dysfunction of heart, brain, lung, or kidney
- History of immunodeficiency or autoimmune disease
- Evidence of tumor recurrence or metastasis before enrollment
- Known hypersensitivity to active ingredients, excipients, monoclonal antibodies, or anti-angiogenic drugs
- History of hepatic encephalopathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhujiang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
S
Shunjun Fu Fu Shunjun Fu, Prof.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here